Patent 6927044 was granted and assigned to Regeneron Pharmaceuticals on August, 2005 by the United States Patent and Trademark Office.
Fusion polypeptides capable of binding interleukin-1 (IL-1) to form a nonfunctional complex are provided and nucleic acid molecules encoding the fusion polypeptides. The fusion ploypeptides form dimers to function as IL-1 antagonists.